These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 16402226)

  • 1. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
    Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4809-15. PubMed ID: 19704123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):765-71. PubMed ID: 15605183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Marley EF; Mohla C; Campos JM
    J Clin Microbiol; 1995 Dec; 33(12):3191-3. PubMed ID: 8586700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.
    Saiman L
    Paediatr Respir Rev; 2007 Sep; 8(3):249-55. PubMed ID: 17868923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
    Moriarty F; Elborn S; Tunney M
    J Microbiol Methods; 2005 May; 61(2):171-9. PubMed ID: 15722142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
    Tunney MM; Scott EM
    J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
    J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
    Massoni-Cristante S; Loiez C; Adriensen B; Husson MO
    Pathol Biol (Paris); 2003 Apr; 51(3):135-42. PubMed ID: 12781793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
    Manno G; Ugolotti E; Belli ML; Fenu ML; Romano L; Cruciani M
    Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):28-34. PubMed ID: 12582741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.
    Saiman L; Mehar F; Niu WW; Neu HC; Shaw KJ; Miller G; Prince A
    Clin Infect Dis; 1996 Sep; 23(3):532-7. PubMed ID: 8879776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.